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Electrical stimulation of the auricular vagus nerve (aVNS) is an emerging technology
in the field of bioelectronic medicine with applications in therapy. Modulation of the
afferent vagus nerve affects a large number of physiological processes and bodily
states associated with information transfer between the brain and body. These
include disease mitigating effects and sustainable therapeutic applications ranging from
chronic pain diseases, neurodegenerative and metabolic ailments to inflammatory and
cardiovascular diseases. Given the current evidence from experimental research in
animal and clinical studies we discuss basic aVNS mechanisms and their potential
clinical effects. Collectively, we provide a focused review on the physiological role
of the vagus nerve and formulate a biology-driven rationale for aVNS. For the
first time, two international workshops on aVNS have been held in Warsaw and
Vienna in 2017 within the framework of EU COST Action “European network for
innovative uses of EMFs in biomedical applications (BM1309).” Both workshops
focused critically on the driving physiological mechanisms of aVNS, its experimental
and clinical studies in animals and humans, in silico aVNS studies, technological
advancements, and regulatory barriers. The results of the workshops are covered
in two reviews, covering physiological and engineering aspects. The present review
summarizes on physiological aspects – a discussion of engineering aspects is
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provided by our accompanying article (Kaniusas et al., 2019). Both reviews build a
reasonable bridge from the rationale of aVNS as a therapeutic tool to current research
lines, all of them being highly relevant for the promising aVNS technology to reach
the patient.
Keywords: auricular vagus nerve, nerve stimulation, biophysics, brain plasticity, inflammation, animal research,
clinical studies
INTRODUCTION
Bioelectronic medicine progressively comes into focus as a
non-pharmaceutical treatment option for various diseases. Here
neuromodulation of the vagus nerve (VN), known also as
wandering or pneumogastric nerve, gained a special interest
in recent years.
This review aims to summarize the contemporary views on the
electrical stimulation of the auricular VN (aVNS) as a promising
electroceutical therapy in humans. Catalysts were the first two
international workshops on aVNS in Warsaw (February 16, 2017)
and Vienna (October 26 and 27, 2017) within the scope of
EU COST Action “European network for innovative uses of
EMFs in biomedical applications (BM1309).” In particular, the
present review summarizes and discusses the physiological role
of VN including a biology-driven rationale for aVNS, backed
up by experimental and clinical data. A focused review on
technical issues, modeling concepts, regulatory requirements,
and novel architectures of aVNS paradigms is provided in our
accompanying article (Kaniusas et al., 2019).
We start with biophysical principles underlying aVNS
and continue with modulation of different body functions
while including experimental data in animals and clinical
data in humans. Future directions of aVNS are identified to
complement this review.
Vagus Nerve
The vagus nerve is the 10th cranial nerve that starts at the
brainstem with two bilateral branches, and widely meanders and
loops within the neck, thorax and abdomen (Trepel, 2017). VN
is composed out of myelinated A and B fibers as well as non-
myelinated C fibers. VN establishes a mutual connection between
the brain and major body structures as pharynx, larynx, trachea,
heart, aorta, lungs, and the entire gastrointestinal tract including
esophagus, stomach, liver, pancreas, and spleen (Berthoud and
Neuhuber, 2000; Standring, 2016). These widespread projections
of VN imply its involvement in many functions of the body’s
autonomic nervous system (ANS). The activity of VN is
proportionally associated with health, wellbeing, relaxation,
and even emotions like empathy, whereas it is negatively
associated with risk factors such as morbidity, mortality, and
stress (Thayer et al., 2009; Zulfiqar et al., 2010). VN thus
plays a crucial role in determining brain-body interactions
(de Lartigue, 2016). These manifold interactions – as best
exaggerated in Clancy et al. (2012) as “My function’s almost
anything, and vagus is my name” – naturally cause increasing
interest in artificial VN stimulation for therapeutic purposes.
VN is considered as a major nerve and thus mediator of the
parasympathetic section of ANS, whereas the vagal tone activates
the parasympathetic nervous system (Olshansky et al., 2008;
Barella et al., 2014).
Most VN fibers (about 80%) are afferent sensory fibers
carrying somatic and visceral information to the brainstem and
thus providing a unique entrance to the brain (Berthoud and
Neuhuber, 2000; Groves and Brown, 2005). In particular, visceral
and cranial homeostatic sensory activity is mediated by input
from VN (and other nerves) to the nucleus of the solitary tract
(NTS) in the lower medulla. As shown in Figure 1A, most
of afferent fibers of VN end in NTS, e.g., for visceral, taste,
heart, and aorta afferents, while other afferents terminate in the
nucleus spinalis of the trigeminal nerve, e.g., for larynx and
pharynx afferents.
The rest of VN fibers (about 20%) are efferent visceromotor
fibers governing neurogenic, myogenic, and endocrine actions
within end organs. These motor fibers originate in the nucleus
ambiguous (for muscle innervation of the pharynx and larynx)
and in the dorsal motor nucleus (to supply heart, lungs,
esophagus, and stomach), as illustrated in Figure 1A. For
instance, the right VN is more closely associated with the cardiac
atria and innervates the sinoatrial node controlling the heart rate
while the left VN is rather associated with the ventricles of the
heart and innervates the atrioventricular node controlling the
contraction force (Guiraud et al., 2016).
Considering our focus on vagus nerve stimulation (VNS), VN
connects specific sensors and effectors in the periphery with the
central nervous system. Mediated connections of VN – within
reach by several synaptic connections – include projections to
hypothalamus and cortex as higher brain regions, thus allowing
modulative access of VN to subcortical and cortical brain areas
(Berthoud and Neuhuber, 2000). Therefore, signals generated
in VN have the potential to affect a broad range of basic
brain functions and thus to affect the entire organism in terms
of its protection.
Sensory Functions
Since VN is mainly a sensory nerve, it essentially relays
biofeedback to the brain, which originates in mechanoreceptors,
chemoreceptors, thermoreceptors, and osmoreceptors spread
throughout the whole body (Berthoud and Neuhuber, 2000;
Szekely, 2000; Williams et al., 2016). Most afferent VN endings
are polymodal responding to a variety of stimuli. Here a direct
activation of free nerve endings of the afferent VN, so-called
primary sensing cells with embedded receptors in the nerve
membrane (Kaniusas, 2012), are likely to be involved; e.g., for the
sense of pain. In addition, an indirect activation of free endings
of the afferent VN is given through synaptically connected
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FIGURE 1 | Natural sensory innervation of the auricle versus its artificial stimulation. (A) The vagus nerve (VN) connects the brain with most of the organs within the
thorax and abdomen. Afferent auricular branches (aVN) leave the cervical VN at the level of the jugular ganglion just outside the cranium and innervate the rather
central regions of the pinna of the outer ear (Peuker and Filler, 2002). (B) Electric stimulation of aVN endings with needle electrodes located within these central
regions. NTS, nucleus of the solitary tract; NSNT, nucleus spinalis of the trigeminal nerve; NA, nucleus ambiguous; DMN, dorsal motor nucleus. This figure and figure
caption was originally published in the sister manuscript to this review (Kaniusas et al., 2019), which was published in Frontiers of Neuroscience under the creative
commons attribution license CC BY 4.0.
specialized cells, so-called secondary sensing cells, e.g., for the
sense of taste (de Lartigue and Diepenbroek, 2016).
To give a few examples, venous baroreceptors (mechano-
receptors) connect to the afferent VN for blood volume
control. Arterial baroreceptors in the aortic arch relay blood
pressure via the afferent VN to the brainstem and thus serve
as feedback for the short-term control of the arterial blood
pressure (baroreflex). Mechanoreceptors and chemoreceptors
in the stomach detect its luminal contents and signal it
via the afferent VN to the brain for the satiety/hunger
response (Williams et al., 2016; Andermann and Lowell, 2017).
Here the afferent VN fibers originate in the mucosa and
muscle layers of the digestive tract. Pulmonary stretch is
also conveyed via the afferent VN to the brain, whereas
mechanoreceptors and chemoreceptors in the respiratory tract
govern the cough reflex. Likewise, mechanical stimulation of
the afferent VN receptors in the diaphragm seems to mediate
the influence of paced breathing to the brainstem activity.
Interestingly, the Valsalva maneuver, vomiting reflex, carotid
sinus massage, and ocular compression can be intentionally
used to alter VN activity (Clancy et al., 2012). The afferent
VN receptors strongly connect enterocrine cells with the brain
(Han et al., 2018) and link this axis to reward sensitivity
(Kaelberer et al., 2018).
The afferent VN carries also nociceptive fibers for pain,
i.e., sensing extremes in temperature, pressure, or chemicals
with high-threshold receptors. For instance, tearing or burning
sensations related to irritation of lower airways are transmitted
mainly through VN afferents. Further, a noxious gastric
distention results in the vagally mediated excitation of NTS,
whereas cardiac ischemia and pain are also mediated by VN
receptors (Berthoud and Neuhuber, 2000).
Body Control via Sensory Functions
Activation of vagal afferents elicits efferent parasympathetic
activation and sympathetic inhibition, like in the baroreflex
(Karemaker, 2017). Therefore, a negative inhibitory feedback is
provided by VN receptors to otherwise feed-forward sympatho-
excitatory activation. As shown in Figure 2A, sensory VN fibers
establish feedback-based control loops with their, in general, non-
linear dynamics. However, since many organs such as the heart
are innervated by both sympathetic and parasympathetic fibers,
it is more precise to speak of the parallel control by both systems
than to stress the antagonistic actions of parasympathetic and
sympathetic systems (Olshansky et al., 2008; Karemaker, 2017).
Sensory fibers in VN provide an excellent opportunity for the
body to detect its homeostasis in the periphery (e.g., immune-
related events) and then to generate appropriate neurogenic,
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FIGURE 2 | Brain modulation via electrical stimulation of auricular vagus nerve (aVN) endings. (A) Intact feedback-loop which is composed out of efferent VN fibers
(controlling different organs and functions) and afferent VN fibers (carrying sensory information back to the brain) for proper control of bodily organs and functions.
(B) Different diseases may lead to a lost or impaired afferent feedback to the brain (e.g., due to neurodegeneration or maladaptive plasticity), which makes it
impossible for the brain (the control station of the body) to adapt to changes in organs, functions, and/or environmental factors. (C) As a hypothesis, stimulation of
aVN fibers substitutes the lost or impaired afferent feedback to the brain while inducing systemic regeneration processes. These processes, in turn, may lead to
sustainable recovery of controlled organs and functions as well as recovery of the relevant sensory feedback-loop.
myogenic, endocrine, and behavioral responses. These responses
involve typically closed-loop reflex pathways along efferent
and afferent pathways (Figure 2A). Central integration and
processing of sensory information and the associated generation
of motor output take place in the brain. Prominent examples
are thermo-regulation, immune-regulation, and blood pressure
control of the body.
For instance, increased arterial blood pressure (hypertension)
stimulates baroreceptors in the aortic arch, signaling via the
afferent VN to the brainstem. The brain, especially, NTS
inhibits reflexively the sympathetic outflow to the heart and
periphery in response to hypertension, whereas the stroke volume
and the total peripheral resistance decrease, respectively. The
parasympathetic outflow via efferent VN fibers is reflexively
accelerated, slowing the heartbeat via the efferent VN connection
to the sinoatrial node of the heart. Consequently, the blood
pressure drops and thus normalizes. One can experience
this vagal-mediated decrease in the heart rate through gentle
rubbing on the vagus nerve via the carotid sinus, a technique
known as carotid massage (Schweitzer and Teichholz, 1985;
Lim et al., 1998).
Collectively, sensory VN seems to provide a powerful back
door into the body, allowing you to “hack the brain” via artificial
stimulation of sensory VN fibers, provided that the electrical
language of nerves is spoken (Moore, 2015).
WHY AURICULAR VAGUS NERVE?
The external ear is the only place on the body where VN sends
its only peripheral branch. In fact, the auricular branch of VN
surfaces as the afferent auricular VN (aVN) and thus forms
a cutaneous receptive field in the pinna of the ear. This field
is susceptible to external stimuli in terms of peripheral nerve
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stimulation. In particular, aVN allows for an easy external access
via electrical stimulation in terms of aVNS, which then connects
directly and favorably the applied stimuli to the brainstem, as
shown in Figure 1B. The brainstem even mediates aVNS input
to higher brain regions via extensive projections to second and
third order neurons within the brain (Mercante et al., 2018b).
The auricle and especially its aVN endings might become a
powerful direct gateway to modulate various brain functions,
offering the most affordable non-invasive manipulation of the
central nervous system.
Even at about 100BC, the auricle’s importance for acupuncture
therapy was recognized as “All the vessels congregate in
the ear” (Sator-Katzenschlager and Michalek-Sauberer, 2007).
Current evidence suggests that even antinociceptive effects of
auricular acupuncture are mediated by the stimulation of aVN
(Usichenko et al., 2017).
Auricular vagus nerve is also known as Arnold’s or Alderman’s
nerve (Nomura and Mizuno, 1984). It leaves the cervical VN at
the level of the jugular ganglion where aVN have their bodies of
the sensory ganglionic neurons, just outside the cranium. aVN
endings provide the sensory innervation of specific regions of the
external ear (Alvord and Farmer, 1998; Kandel et al., 2000; Peuker
and Filler, 2002; He et al., 2012). As illustrated in Figure 1A,
the middle region of the pinna, the central concha, is mostly
innervated by aVN, whereas aVN was found in 100% of cases in
cymba concha (Peuker and Filler, 2002). Other ear regions such
as antihelix, cavity of concha, tragus, crus of helix, and crura of
antihelix were found to be partly but non-exclusively innervated
by aVN in 73, 45, 45, 20, and 9% of cases, respectively (Peuker
and Filler, 2002). aVN is composed out of myelinated Aβ fibers
(fibers with the diameter 7–10 µm comprise about 20% of the
total myelinated aVN axons with about 370 myelinated axons per
auricle), myelinated Aδ fibers (fibers with the diameter 2–5 µm
comprise about 50% of the total myelinated aVN axons) (Safi
et al., 2016), and non-myelinated C fibers (Standring, 2016).
Besides aVN endings, the ear contains endings of non-vagal
cervical and cranial nerves such as the great auricular nerve
(e.g., present in the ear lobe), the auriculotemporal nerve (e.g.,
the branch of the trigeminal nerve located in the spine of
helix), and the lesser occipital nerve (e.g., the upper third of
the medial surface of the auricle) (Peuker and Filler, 2002).
From an anatomical point of view, all nerve fibers in the
auricle run between the ear cartilage and skin in a depth of 1–
1.5 mm (Bermejo et al., 2017). From a functional point of view,
different physiological effects can be expected when stimulating
locally different areas in the ear. For instance, variable intensity
of induced autonomic changes was shown as a function of
the area of stimulation in rats (Gao et al., 2007), whereas a
significantly stronger activation of the NTS was proven when
the cymba concha region was electrically stimulated in humans
compared to sham stimulation and other auricular regions
(Yakunina et al., 2016).
Auricular vagus nerve stimulation recruits sensory aVN fibers
and thus mimics/projects sensory input to the brainstem in
terms of neuromodulation, forming the so-called auriculo-vagal
afferent pathway (He et al., 2013). Since aVNS projects directly
to NTS (Figure 1A), both ANS and the central nervous system
are modulated by aVNS. Consequently, since ANS, composed out
of sympathetic and parasympathetic branches, governs systemic
parameters of cardiovascular, respiratory, and immunological
functions to stay within their homeostatic limits and, on the other
hand, aVNS modulates the parasympathetic auricular branch,
aVNS effects on the body can be expected to be systemic.
Systemic effects affect multiple physiological functions and
are not specifically targeted to a particular organ or an isolated
function. For instance, the sympathovagal balance – as a systemic
parameter of the body – can be modulated for therapeutic
reasons. In line with the aforementioned inhibitory effects
of vagal receptors, systemic effects of aVNS can expected
to be mostly from the sympatho-inhibitory origin (Deuchars
et al., 2017). As illustrated in Figure 2A, aVNS modulates the
biofeedback line to the brain so that this modulation shapes
closed-loop reflex pathways, in analogy with neurobiological
models from De Couck et al. (2011). Therefore, once again,
diverse systemic effects of aVNS can be expected on the
entire organism.
From an evolutionary developmental perspective, aVN is
all that remains of a more extensive embryonic nerve which
supplies the first branchial arch and is supposed to be the last
phylogenetic remnant of the nerve innervating the lateral line
organs in fish and amphibia (He et al., 2013). Interestingly, the
sensory auricular nerve endings (including aVN) in mammals
may have evolved from the mandibular/jaw area in the
course of the evolutionary transition when post-dentary jaw
elements moved to the cranium as auditory ossicles (Meng
et al., 2011). This evolutionary development may justify some
current complex pathways of aVN action in the pharynx area
and may shed some light on the physiological relevance of
aVN endings today.
VAGUS NERVE STIMULATION – FROM
BIOPHYSICS TO ANIMAL AND TO
HUMAN DATA
Auricular vagus nerve stimulation is a peripheral, non-
pharmacological, and minimally invasive neuromodulation
technique, altering signal processing in the central nervous
system, activating reflex circuitries, exploiting brain plasticity
for different therapeutic purposes, and thus affecting profoundly
different areas of the brain, as described below. The broad
range of brain versus periphery projections of VN and its
corresponding functions suggest a large variety of disorders
possibly indicated for aVNS therapy in humans, whereas these
disorders share common features related to the protective
function of VN. This simple peripheral technique of aVNS
gains access to central pathways of the brain. Due to systemic
effects of aVNS – and, in general, of any VNS – many different
biophysical mechanisms have been found to be modulated,
including ANS affecting the whole organism. Though the
exact mechanisms of aVNS and VNS remain to be elucidated,
the following neurophysiological evidence and modulation of
different body functions are based on strong hypothesis derived
from experimental animal and clinical human data.
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With the critical assumption that observed neurophysiological
effects of aVNS and VNS may be considered as being similar
(see below), here we review both implanted VNS and non-
implanted minimally invasive aVNS in animal models. In fact,
tightly controlled settings in experimental animal studies allow
for potentially more consistent findings in bio-physiological basic
mechanisms behind aVNS than human studies. In addition,
observed effects in animals indicate potential applications
of aVNS in humans.
In the reviewed human studies, we focus on clinical evidence
of transcutaneous and percutaneous aVNS, whereas a lot of
populations have been found to benefit from aVNS therapy, as
summarized in Figure 3. Although randomized clinical trials
on aVNS are accumulating, a lot of them are preliminary case
studies. For human studies with potential clinical applications,
we differentiate explicitly between clinical trials, case studies,
and reviews to qualify the strength of statement. Studies on
auricular electroacupuncture or peripheral nerve stimulation
are also included if stimulation electrodes were located in
vagally innervated regions of the auricle (Figure 1A). Therefore,
applications of the implanted VNS in humans – the therapy
which became established during the past 20 years (Beekwilder
and Beems, 2010) – are excluded in order to focus on aVNS only.
Neurophysiological Evidence –
Modulation of Brain Function, Reflex
Loops, and Brain Chemistry
Peripheral aVNS modulates various central brain structures
involved in autonomic control and in motor control, especially
via projections from NTS and nucleus spinalis of the trigeminal
nerve, whereas the main therapeutic target is NTS (Figure 1A). In
the following, we summarize different methods used to validate
this modulation.
(i) Functional magnetic resonance imaging has shown specific
modulation of various brain structures following aVNS.
These structures include the brainstem and its nuclei NTS
and nucleus spinalis of the trigeminal nerve (Chae et al.,
2003; Kraus et al., 2007, 2013; Dietrich et al., 2008), and
are mostly associated with the higher order relay of afferent
(visceral and somatic) VN pathways and networks (Badran
et al., 2017). These modulated structures are involved
in autonomic regulation, alertness, mood, and well-being
control. The brain activation patterns in aVNS were shown
to be similar to those during the implanted cervical
VNS (Beekwilder and Beems, 2010), indicating favorably
similar therapeutic effects of non-invasive and invasive
VNS (Mercante et al., 2018b). Most interestingly, activation
and deactivation patterns of the brain in response to aVNS
over-lasted the effective duration of the stimulation – e.g.,
by as much as 11 min after cessation of cymba concha
stimulation (Frangos et al., 2014) – providing support for
the hypothesis of long-lasting sustainable effects of aVNS.
(ii) Evoked far-field brainstem potentials have been reported in
response to aVNS since activation of vagal afferents evokes
vagus somatosensory potentials in the brain (Fallgatter
et al., 2003; Polak et al., 2009). In particular, these potentials
reflect the postsynaptic brainstem activity and thus can be
regarded as a measure for the brain modulation following
aVNS. These brainstem potentials presumably originate in
vagal nuclei such as NTS (Fallgatter et al., 2003; Polak
et al., 2009) and, again, are similar to evoked potentials
from implanted VNS (Nonis et al., 2017). Interestingly,
potentials show longer latencies in the elderly than the
younger participants (Fallgatter et al., 2004).
(iii) Extracellular recordings in the brain have shown that
the percutaneous aVNS decreases spontaneous firing of
neurons in the central nervous system – namely, in the
central nucleus of the amygdala – by about 50% (Babygirija
et al., 2017), which confirms inhibitory effects of aVNS.
For instance, the suppression of epileptiform activity was
observed via activated firing of NTS neurons in response
to aVNS (He et al., 2013). Inhibitory effects of VNS
were shown in animal models (Lockard et al., 1990). In
particular, motor activity and brainstem neuronal activity
were inhibited in cats, as well as the tail-flick reflex in rats.
Here a consistent animal alertness was commonly used to
find the stimulation threshold indicating inhibitory effects
and moreover to ensure comfort and safety of animals.
(iv) Significant changes in the resting electroencephalogram,
especially, activation of the mediofrontal theta band,
have been observed in response to the implanted VNS
(Bonaz and Pellissier, 2016).
(v) Transcranial magnetic stimulation was used to prove
increased intracortical inhibition in response to
aVNS, most likely due to increased GABAergic activity
(Capone et al., 2014).
Auricular vagus nerve stimulation has the potential to
improve neuronal plasticity provided that plasticity is
maladaptive (Clancy et al., 2012; Lehtimaki et al., 2012).
For instance, the invasive VNS paired with auditory stimuli
were shown to reverse pathological changes of the cortex in a
rat model of tinnitus (Engineer et al., 2011). Since the intact
brain plasticity follows different time scales, from quite fast
changes within seconds up to slow changes within weeks up
to 1 year, aVNS effects can be expected to follow these time
scales. In addition, artificial neuromodulation of VN positively
affects impaired synchronicity of synaptic activities between
and within brain regions as well as overly excited or even
deficient reflexes involving central brain pathways (Oleson, 2002;
Beekwilder and Beems, 2010). VNS and even aVNS may activate
reflexes which inhibit maladaptive reflexes of neuromuscular
disorders in humans (Kampusch et al., 2015a) as well as may
modulate nociceptive reflexes in rats, namely, facilitate them
at low VNS intensities and inhibit at high intensities (Ren
et al., 1988, 1993). All these detrimental changes in the brain
and reflexes are usually present in chronic diseases such as
chronic pain or chronic muscle spasms, which are thus possible
application fields of aVNS.
Figure 2B illustrates schematically how the sensory feedback
to the brain is lost or impaired – in contrast to intact feedback-
loops from Figure 2A – due to the aforementioned detrimental
changes in the brain and reflexes, due to maladaptive plasticity
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FIGURE 3 | Reported clinical applications of the auricular vagus nerve stimulation (aVNS) in humans. The total area of the pie chart indicates the total number of
publications reviewed, whereas individual pieces refer to the respective numbers of clinical trials, case studies, and reviews.
and neurodegeneration. Since aVNS recruits sensory fibers to
the brainstem (Figure 1), aVNS could be hypothetically expected
to mimic the sensory feedback to the brain (Figure 2C),
circumventing temporally a lost or impaired feedback. For
instance, the invasive and selective stimulation of the cervical
VN was used to mimic baroreceptor signals to lower the
blood pressure in rats (Plachta et al., 2014, 2016). In analogy,
the baroreflex sensitivity was improved by aVNS in humans
(Antonino et al., 2017), thus affecting processing of afferent
signals in the brain. In addition, aVNS seems to have the potential
to restore the missing or altered signaling of intestinal VN
afferents (Guiraud et al., 2016).
More importantly, aVNS in Figure 2A could be hypothesized
to be followed by sustainable regeneration mechanisms which
re-establish the impaired sensory information flow to the brain,
as a basis for systemic and sustainable treatment of disease via
aVNS. The sustainability of aVNS was demonstrated not only on
the brain level, as discussed above with respect to Frangos et al.
(2014), but also on physiological level. For instance, the activation
of the anti-inflammatory response required only a brief VNS
stimulus and lasted for more than 24 h (Olofsson et al., 2015).
A sustained antinociceptive effect of aVNS was observed in
pain-related gastrointestinal disorders for an extended period of
9 weeks after 3 weeks of treatment (Kovacic et al., 2017), as well as
in chronic low back pain for a 3 months follow-up after 6 weeks
of treatment (Sator-Katzenschlager et al., 2004).
In response to VNS, endogenous opioid neuropeptides
(endorphins) are released in the central nervous system as
well as various neurotransmitters (enkephalins and substance
P). The release alters properties of neuron membranes, the
neuron’s response to synaptic events, and thus alters excitation
or inhibition of neuron firing. Consequently, neuronal networks
can be potentially reprogramed by VNS, in line with the discussed
neuroplasticity. Interestingly, the release of neuropeptides due
to aVNS seems to depend on the stimulation frequency
(Sator-Katzenschlager and Michalek-Sauberer, 2007). A relatively
low frequency of 2 Hz accelerates the release of enkephalin,
β-endorphin, and endomorphin. In contrast, a high frequency of
100 Hz selectively increases the release of dynorphin.
Vagus nerve stimulation seems to modulate serotonergic,
noradrenergic, and endorphinergic pathways in different brain
regions by the relay projections of the vagal afferent nuclei. The
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associated release of serotonin, norepinephrine, and endogenous
opioids is increased while modulating chemically the nociceptive
processing in the brain (Lockard et al., 1990; Oleson, 2002;
Lehtimaki et al., 2012), the mood and anxiety control, and the
pathophysiology of depression (Beekwilder and Beems, 2010;
Chakravarthy et al., 2015; Conway and Xiong, 2018; Mercante
et al., 2018b). Even aVNS increased norepinephrine levels in
rats (Li et al., 2015b). Increased release of noradrenaline in the
brain seems to follow VNS, as well as increased amounts of the
inhibitory transmitter GABA in the cerebrospinal fluid (Groves
and Brown, 2005) and NTS (Mercante et al., 2018b), which
potentially leads to VNS-mediated seizure reduction (Clancy
et al., 2012) and antidepressant effect (Mercante et al., 2018b).
VNS inhibits excitatory glutamate release (Chen et al., 2015c).
VNS increases the release of neurotrophic factors as well as
stimulates cellular proliferation and neurogenesis in the brain,
which have been associated not only with antidepressant effects
but also neuronal plasticity, memory, learning and cognitive
processes (Mercante et al., 2018b).
In fact, the actual stimulation pathway of aVNS is highly
indirect with respect to the distant pathological organ or
addressed functions of the body, since aVN has a transmitting but
not a processing function. In particular, the stimulation pathway
is circuitous. The pathway of the therapeutic electric stimuli starts
with action impulses traveling from the peripheral somatosensory
aVN endings in the auricle to the brainstem and then to higher
order brain structures. Then, the pathway goes either from cranial
nerves to the correspondent region of the body or, in analogy,
from the brain to the spinal cord and then from spinal nerves
to the target body’s region. Both somatic efferent arms (see
section “Pain – Experimental Evidence”) and autonomic efferent
arms (see section “Modulation of Autonomic Function”) can be
expected to be modulated. Distant targets are thus affected via
neurological networks or reflexes.
Epilepsy
Both VNS and aVNS reduced epileptic seizure activity in rats (He
et al., 2009) via activated firing of neurons in NTS (He et al.,
2013). Authors in Zagon and Kemeny (2000) suggest a vagally
mediated hyperpolarization and thus reduced excitability of
cortical neurons that otherwise would be involved in propagation
of seizures. VNS decorrelated cortical synchrony and rhythmicity
in rats indicating a potentially reduced seizure activity (Nichols
et al., 2011). The period of protection from seizure activity
persisted beyond the stimulation period (Schachter and Saper,
1998), whereas VNS and aVNS showed similar durations of the
anti-seizure effect (Ellrich, 2011).
In humans, aVNS reduced seizure frequency in epilepsy as
well as the intensity and duration of seizures, as shown in clinical
trials (Rong et al., 2014; Bauer et al., 2016), a case series (Stefan
et al., 2012), and reviewed in Beekwilder and Beems (2010) and
Shiozawa et al. (2014). The required dosage of antiepileptic drugs
was also reduced (Beekwilder and Beems, 2010).
Depression
Melatonin secretion in response to aVNS ameliorated the innate
depressive behavior in diabetic rats (Li et al., 2014). The
antidepressant effect of aVNS was also demonstrated in rats
with suggested cardio-inhibitory effects, possibly mediated via
the normalization of the hypothalamic-pituitary-adrenal axis
hyperactivity in major depression (Liu et al., 2013).
In humans, clinical improvement of depression was shown
when treated with the transcutaneous aVNS, whereas depression
scores as well as remission rates improved, see clinical trials
(Kraus et al., 2007; Hein et al., 2012; Fang et al., 2015; Rong et al.,
2016) and a review (Shiozawa et al., 2014).
Stroke
Auricular vagus nerve stimulation reduced significantly the
infarct volume and improved neurological scores after cerebral
ischemia in rats (Ay et al., 2014), whereas only an insignificant
reduction in the lesion size was observed after ischemic stroke
in rats (Hays et al., 2016). aVNS improved neurobehavioral
recovery and upregulated cerebral growth differentiation factor
11 – a rejuvenation factor participating in brain angiogenesis
almost in parallel to neurogenesis after stroke – in cerebral
ischemia/reperfusion rats (Ma et al., 2016). The transcutaneous
aVNS in humans was shown to improve rehabilitation in stroke
according to a clinical trial in Capone et al. (2017). These reports
indicate aVNS as a potential therapy target for stroke.
Invasive VNS paired with rehabilitative training significantly
improved recovery of forelimb function in rats after both
intracerebral hemorrhage (Hays et al., 2014) and ischemic stroke
within the motor cortex (Hays et al., 2016). Here the sensory
inflow along VN potentially provides an associative component
to neuronal plasticity in the brain, which enhances plasticity. This
may indicate a potential use of aVNS paired with movements to
improve cortical representation of movements in the treatment
of movement disorders, including the rehabilitation of stroke
patients (Porter et al., 2011).
Other Disorders
Vagus nerve stimulation improved recovery after traumatic brain
injury in rats, based potentially on enhanced neural plasticity
and enhanced norepinephrine release (Smith et al., 2005). VNS
has shown efficacy in enhancing memory storage processes,
as mediated by stimulation of VN afferents in rats (Clark
et al., 1998). Furthermore, VNS facilitated visceral pain-related
emotional affective memory (Zhang et al., 2012) and enhanced
the extinction of conditioned fear when paired with extinction
training (Peña et al., 2012) in rats.
In humans, the transcutaneous aVNS is a promising treatment
method for autism spectrum disorders and a lot of other
psychiatric disorders, as reviewed in Cimpianu et al. (2016)
and Jin and Kong (2017), respectively. However, aVNS failed
to improve schizophrenia symptoms, as recognized by a clinical
trial in Hasan et al. (2015).
In addition, positive effects in Alzheimer’s disease can also
be potentially expected because decreased norepinephrine levels
are raised by VNS, the levels being essential in maintaining
adequate beta amyloid clearance and thus preventing Alzheimer
(Beekwilder and Beems, 2010). The neuroprotective role of aVNS
was shown in a mouse model of Alzheimer disease (Kaczmarczyk
et al., 2017). Interestingly, evoked far-field brainstem potentials
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after aVNS have been proposed to be used for an early diagnosis
of dementias and Alzheimer’s disease, see clinical study in Polak
et al. (2007). In particular, latencies of these potentials increase
in disease due to degeneration of nervous structures of vagal
parasympathetic nuclei.
Modulation of Nociceptive Processing
The central sensitization represents enhanced excitability of
nociceptive pathways due to maladaptive plasticity of the
central nervous system [e.g., in the superficial dorsal horn
(Todd, 2010)] in response to hyperactivity, inflammation,
and neural injury (Latremoliere and Woolf, 2009). This
sensitization seems to be a key factor to potentiation in
pain sensibility in acute and chronic pain while recruiting
previously subthreshold synaptic inputs to excitatory nociceptive
pathways. Hyperalgesia can also be produced by illness-inducing
agents such as bacterial cell wall endotoxin lipopolysaccharide,
whereas these agents activate VN afferents in terms of
immunosensation, i.e., sensation of immune-relevant substances
(Watkins et al., 1994). The inhibitory and desynchronizing
actions of VNS together with enhanced brain plasticity and
activated serotonergic pathways (see section “Neurophysiological
Evidence – Modulation of Brain Function, Reflex Loops,
and Brain Chemistry”), as well as anti-inflammatory effects
of VNS (see section “Modulation of Inflammation”), all can
be hypothesized to counteract the maladaptive plasticity and
inflammation of the central sensitization and thus to counteract
pain hypersensitivity. These actions of VNS may potentially
contribute to antinociceptive aVNS effects in hyperalgesia, with
the aforementioned assumption of similar neurophysiological
effects of VNS and aVNS (Beekwilder and Beems, 2010;
Mercante et al., 2018b).
Gating mechanisms may become indirectly modulated by
aVNS for antinociception, as related to the well-known
concordant paresthesia. That is, pain mediated by Aδ and/or C
afferents is alleviated by touch or by a simultaneous activation
of tactile Aβ afferents from a homotopic site (Ellrich and Lamp,
2005). For instance, hitting a finger can induce pain which can
be compensated by rubbing fingers. In particular, the activation
of Aβ fibers can inhibit transmission of nociceptive signals in
that excited Aβ fibers inhibit presynaptic terminals of Aδ and/or
C fibers (Sandkühler, 2000), which is known as activation of
inhibitory pain control systems. This leads to wind-down of pain-
induced changes in the signal transduction within the spinal
cord (Sandkühler, 1996). The electrophysiological data provide
evidence that electric stimulation of peripheral Aβ fibers reliably
suppresses Aδ fiber nociceptive processing in human volunteers
(Ellrich and Lamp, 2005).
Since the stimulated Aβ afferents in the auricle and nociceptive
signals along Aδ and/or C afferents do not originate in homotopic
sites, we cannot expect a direct activation of gating mechanisms
on the spinal level via aVNS. However, since aVN projects
via NTS to numerous other brainstem complexes (Nomura
and Mizuno, 1984) mutually interacting with spinal regions
involved in pain processing (e.g., dorsal horn neurons), an
indirect modulation of gating mechanisms can be hypothesized.
In addition, aVNS may co-recruit non-vagal auricular nerves
(e.g., the great auricular nerve) which end in spinal regions
(Mahadi et al., 2019) and thus may directly interfere with gating
mechanisms there.
Gating may also refer to blockage of nociceptive signals from
ascending peripheral nerves to the brain by descending impulses
from the brain (Oleson, 2002). Not only ascending nociceptive
stimuli are disrupted but also descending nociceptive signals into
the gray matter of the dorsal horn of the spinal column are
mitigated (Roberts et al., 2016).
In addition, encephalin-containing interneurons within the
spine are proposed to be activated resulting in the inhibition
of conduction of pain signals to the brain (Sator-Katzenschlager
and Michalek-Sauberer, 2007). Single neuron studies reveal that
activation of vagal afferents mostly inhibits nociceptive neurons
in the spinal cord in response to noxious stimuli, especially at
greater intensities of VNS; e.g., 77% of observed spinothalamic
tract neurons were inhibited (Ren et al., 1991). Interestingly,
the effective inhibition of nociceptive processing in humans can
even outlast conditioning electric stimuli (Ellrich and Lamp,
2005), which may theoretically lead to short-term and even long-
term afferent-induced analgesia (Sandkühler, 2000) in response
to aVNS (Sator-Katzenschlager et al., 2004).
For effective antinociception using peripheral nerve
stimulation, a non-painful stimulus is required to excite
rapidly conducting thick myelinated Aβ fibers but not
nociceptive slowly conducting thin myelinated Aδ and thin
non-myelinated C fibers. Please note that excitation thresholds
of Aβ fibers are lower than those of Aδ and C fibers because
both myelinization and increasing fiber thickness reduce
their threshold (Kaniusas, 2019). Therefore, the nociceptive
threshold in different nerves was found to be 5–7 times larger
than the detection threshold, whereas near maximal activation
of Aβ fibers was suggested to be only 4 times the detection
threshold (Ellrich and Lamp, 2005). For comparison, the activity
of the least excitable C fiber can be evoked by stimuli with
intensities 15–20 times the detection threshold (Ellrich and
Lamp, 2005); in line with (Guiraud et al., 2016) stating that the
activation threshold of C fibers is 10–100 times greater than
that of A fibers.
However, the requirement of the recruitment of non-C-fibers
for antinociception in peripheral nerve stimulation contrasts
with experimental investigations on the invasive VNS and
thus potentially indicates different mechanisms of action in
aVNS and in VNS. That is, single neuron studies in rats (Ren
et al., 1988, 1991) and targeted pharmacological blunting of
C-fibers (Ren et al., 1993) indicate that a low-intensity VNS
accelerates discharges of nociceptive neurons in the spine,
facilitates nociceptive reflexes and thus produces pronociception,
and suggests activation of low-threshold myelinated non-C-fibers
of the stimulated afferent VN. In contrast, a high-intensity VNS
yields opposite effects of antinociception due to the activation of
high-threshold C-fibers but not low-threshold myelinated non-
C-fibers of the afferent VN (Ren et al., 1993).
In general, stimulated VN afferents can exert both inhibitory
and excitatory modulation of the nociceptive processing in spinal
and supraspinal regions, in central and peripheral pain pathways
(Berthoud and Neuhuber, 2000; Busch et al., 2012; Napadow
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et al., 2012). Low stimulus intensities applied in the afferent
invasive stimulation of VN tend to induce pronociception
(Ren et al., 1988; Ness et al., 2000) while high intensities –
still non-noxious but perceivable stimuli – tend to induce
antinociception (Chakravarthy et al., 2015). In line with (Randich
and Gebhart, 1992), antinociceptive inhibiting effects of VNS
begin to counteract pronociceptive facilitatory influences of
VNS with increasing VNS intensity. However, some controversy
exists concerning pronociception in response to the afferent
stimulation of VN (Busch et al., 2012). Some human subjects
with implanted VNS have even shown U-shaped thermal pain
thresholds with increasing VNS intensity (Ness et al., 2000).
Authors in Laqua et al. (2014) report both antinociception
and pronociception in response to aVNS in about 70 and 30%
of healthy subjects, respectively, accounting this to individual
sensitivity. As a hypothesis supported by the authors, low and
high intensity VNS may potentially activate different circuits
in the brainstem.
Furthermore, stimulation of vagal afferents with the
subsequent neuromodulation of NTS (Figure 1A) is
hypothesized to underlie the antinociceptive effects of VNS
(Napadow et al., 2012). This is because NTS acts as an integrating
station for nociceptive afferent stimuli (Boscan et al., 2002) and
as a relay station and inputs to higher brain regions, which
process and modulate different aspects of pain (Saper, 2002).
Furthermore, spinal regions processing pain project to NTS
(Todd, 2010), such as the dorsal horn neurons (Mahadi et al.,
2019). For instance, an electrical stimulation of NTS was shown
to inhibit nociceptive responses at the spinal cord level (Du and
Zhou, 1990), whereas a local anesthetic block of NTS eliminated
the inhibitory effect of VN stimulation on the nociceptive tail
flick reflex in rats (Randich and Aicher, 1988). Authors in
Napadow et al. (2012) have shown less antinociceptive effects in
an auricular non-VN stimulation as compared to the auricular
VN stimulation mediated by NTS.
Pain – Experimental Evidence
In animals, VNS attenuated heat-induced and formalin-induced
pain in rats (Bohotin et al., 2003). aVNS increased paw
withdrawal threshold in rats and attenuated baseline firing of
neurons in the central nucleus of the amygdala and spinal cord
neurons by about 50%, which may account for the modulation
of pain responses (Babygirija et al., 2017). VNS was shown
to inhibit cortical spreading depression, a propagating wave of
depolarization that underlies migraine aura and thus triggers
headache in rats (Chen et al., 2015c). Interestingly, the non-
invasive VNS on the neck demonstrated the potential to alleviate
trigeminal allodynia in rats (Oshinsky et al., 2014). This type
of VNS decreased levels of the extracellular glutamate in the
trigeminal nucleus caudalis, a neurotransmitter that increases
with trigeminal pain.
In humans, the electrical stimulation of auricular regions
including aVN increased electrical pain thresholds by 30–50% in
about half of the studied healthy subjects (Johnson et al., 1991),
increased mechanical and pressure pain thresholds (Beekwilder
and Beems, 2010; Busch et al., 2012), as well as increased pressure
pain thresholds and decreased pain ratings under sustained
application of painful heat (Ellrich et al., 2011). Once again,
predominant inhibitory effects of aVNS are highlighted by
these cited studies.
Pain – Clinical Evidence
Antinociceptive effects of aVNS were shown in numerous clinical
trials: chronic cervical pain (Sator-Katzenschlager et al., 2003),
chronic low-back pain (Sator-Katzenschlager et al., 2004), acute
pain during in vitro fertilization (Sator-Katzenschlager et al.,
2006), postoperative pain after laparoscopic nephrectomy (Likar
et al., 2007), postoperative pain after tonsillectomy (Kager
et al., 2009) – as also supported by a review (Cho et al.,
2015) – postoperative pain after hysterectomy (Tsang et al.,
2011), headache syndrome (Busch et al., 2012), high-frequency
and chronic migraine (Straube et al., 2015), acute migraine
(Garcia et al., 2017), chronic abdominal pain-related functional
gastrointestinal disorders (Kovacic et al., 2017), and chronic
pelvic pain (Napadow et al., 2012). A few case studies support
antinociceptive effects of aVNS, namely, in postoperative pain
(Szeles et al., 2001) – as also supported by a review (Liu et al.,
2015) – chronic muscle pain in dystonia (Kampusch et al.,
2015a), pain in peripheral arterial occlusive disease (Payrits
et al., 2011), pain in primary Raynaud’s syndrome (Schlager
et al., 2011), labor pain (Grünberger et al., 2005), and finally in
diverse musculoskeletal pain disorders (unpublished data by our
group in Vienna).
The percutaneous aVNS significantly reduced opioid intake,
such as tramadol (Sator-Katzenschlager et al., 2003, 2004),
remifentanil (Sator-Katzenschlager et al., 2006), morphine-
hydrochloride (Likar et al., 2007), naproxen and tramadol (Kager
et al., 2009), all latter studies are clinical trials, and morphine,
as reviewed in Liu et al. (2015). aVNS reduced anesthetic
requirements in response to noxious electrical stimulation, as
shown in a clinical trial (Greif et al., 2002) and reduced analgesic
medication intake after abdominal and accident/trauma surgery,
as shown by a case series in Szeles et al. (2001).
However, the percutaneous aVNS in the following clinical
trials failed to show reduced acute pain and reduced analgesic
consumption in the perioperative setting of the third molar
tooth extraction (Michalek-Sauberer et al., 2007), as well
as aVNS failed to reduce postoperative pain and opioid
consumption in women undergoing elective gynecological
laparoscopy (Holzer et al., 2011).
In general, results for aVNS are controversial in acute pain
but are rather consistent in chronic pain (Sator-Katzenschlager
and Michalek-Sauberer, 2007). This suggests that aVNS may be
rather a long-term adjunctive therapy for treating chronic pain
than an acute treatment (Clancy et al., 2012). In fact, chronic
pain and acute pain are two different processes. Acute pain is
a physiological process with well-defined anatomical pathways
underlying the perception of nociception. In contrast, chronic
pain is a pathological state associated to the complex rewiring of
circuitries of the central nervous system, reported as maladaptive
plasticity (Colangelo et al., 2014).
Auricular vagus nerve stimulation decreased symptoms of
acute opioid withdrawal – related to heroin, methadone and
others – after just 1 h of stimulation and allowed for an
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effective transition to non-opioid assisted medication therapy
in some patients, as illustrated by a retrospective case series in
Miranda and Taca (2017). aVNS was shown to be associated with
temporary relief of withdrawal symptoms in heroin-addicted
subjects on and after treatment in the first 3 days, see a case series
in Wen et al. (1978).
Modulation of Inflammation
Inflammation processes are governed through interrelated
humoral and neural reflex pathways (Tracey, 2009; Miller and
Raison, 2015). In particular, chronic inflammation is based
on deregulation of metabolic and immune functions, whereas
the imbalance between pro-inflammatory and anti-inflammatory
cytokines seems to be decisive in disease progression (Neurath,
2014). Abnormal and chronic inflammation is implicated in,
causes and advances, numerous wide-spread chronic diseases as
diabetes mellitus and is, for example, a major hindering factor in
effective neuroprotection in the brain, e.g., after stroke.
The vagus nerve provides a first-line defense against infection
and inflammation in the periphery to restore homeostasis
via conducting information to/from the brain to regulate
the immune system. VN is a major component of the
neuroendocrine-immune axis (Bonaz and Pellissier, 2016).
For instance, even fever, as a brain-mediated response, is
signaled to the brain via afferent VN responding to peripheral
proinflammatory cytokines, in addition to blood-borne routes for
the fever’s signaling (Hansen et al., 2001).
The parasympathetic outflow along VN, i.e., activation of
the parasympathetic system, has only anti-inflammatory effects.
This was shown by the inverse relationship between VN-
mediated parasympathetic markers of the heart rate variability
(HRV) and inflammatory markers (Thayer and Fischer, 2008).
In contrast, the sympathetic nervous system may have both
pro-inflammatory and anti-inflammatory effects.
In general, VN is involved in mainly three reflex pathways with
a clear anti-inflammatory role:
(i) The anti-inflammatory hypothalamic-pituitary-adrenal
axis. Here afferent VN fibers sense the level and location
of injury/infection in that pro-inflammatory cytokines
and/or endotoxins activate VN endings. Somatotopic
maps in NTS become activated. Consequently, special
neurons in hypothalamus activate the release of hormone
adreno-corticotrophin by the hypophysis, stimulating the
release of glucocorticoids by the adrenal glands to decrease
peripheral inflammation.
(ii) The anti-inflammatory vago-vagal reflex, known also as
the cholinergic anti-inflammatory pathway (Borovikova
et al., 2000; Tracey, 2007). Here infection-activated afferent
VN fibers synapse with and generate an outflow along
efferent VN fibers releasing acetylcholine at their synaptic
endings. The acetylcholine binds to surface receptors of
macrophages and suppresses the production and release of
pro-inflammatory cytokines by these macrophages.
Interestingly, the tonic neural activity of this cholinergic
anti-inflammatory pathway is essential because, when it is
impaired, over-inflammation results with an unrestrained
cytokine release damaging tissue (Mercante et al., 2018a).
From this perspective, VNS enhances the activity of
immune-related neural circuits and confers protection
of the human body.
(iii) The splenic sympathetic anti-inflammatory pathway. Here
the infection-activated afferent VN yields outflow along the
efferent VN which stimulates the adrenergic sympathetic
nerve in the spleen, releasing norepinephrine at its endings.
Then norepinephrine binds to splenic lymphocytes
and leads to acetylcholine release by lymphocytes,
whereas acetylcholine, in turn, inhibits the release of
pro-inflammatory cytokines by splenic macrophages.
Thus, the innate immune system is subjected to a closed-
loop reflex modulation via afferent VN fibers, as illustrated
in Figure 2A, whereas the activity of the efferent VN
maintains homeostasis by limiting pro-inflammatory responses
and avoiding immunosuppression. For instance, the role of VN is
proposed in informing the brain about peripheral inflammation
related to coronary artery disease and in actively modulating the
disease related inflammation (Gidron et al., 2006).
An artificial VNS has been shown to harness this natural reflex
(Figure 2C). The modulation of VN results in decreased pro-
inflammatory and increased anti-inflammatory cytokines, which
is effective in suppression of over-inflammation, prevention
of tissue injury, and improved survival. For instance, aVNS
reduced pro-inflammatory cytokines, as shown in a clinical trial
(Stavrakis et al., 2015), and increased norepinephrine levels, as
reviewed in Beekwilder and Beems (2010), which supports anti-
inflammatory aVNS effects.
In particular, VNS was shown to rebalance the working point
of autonomic regulation of the immune system into a protective
range avoiding pro-inflammatory responses and, on the other
hand, avoiding immunosuppression (Tracey, 2009). Here the
working point is defined as the magnitude of innate immune
responses relative to the infection or injury stimulus. Chronic
changes can unfavorably increase or decrease the working point
with the resulting overshooting immune response (with tissue
damage, sepsis, or even death) or immunosuppression (with
secondary infections), respectively.
In animals, VNS had favorable effects on rheumatoid arthritis
in rats (Koopman et al., 2017). VNS reduced surgery-induced
intestinal inflammation and improved postoperative intestinal
transit in mice, supporting the anti-inflammatory effect of
VNS (Matteoli et al., 2013). In addition, VNS prevented the
development of shock in rats through inhibited synthesis
of the tumor necrosis factor (cytokines) (Borovikova et al.,
2000). aVNS was shown to be efficient in mice with lethal
endotoxemia or polymicrobial sepsis while reducing systemic
tumor necrosis factor due to anti-inflammatory aVNS effects
(Huston et al., 2007). aVNS suppressed lipopolysaccharide-
induced inflammatory responses in endotoxemic rats through
reduced pro-inflammatory cytokines, indicating that aVNS
modulates the immune function through the cholinergic anti-
inflammatory pathway (Zhao et al., 2012).
In humans, potential therapeutic applications of aVNS
are related to chronic inflammatory conditions. These are
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rheumatoid arthritis, see a clinical trial in Becker (2007),
inflammatory bowel disease (Crohn’s disease, ulcerative colitis),
and postoperative ileus in order to restore intestinal homeostasis,
as reviewed in Tracey (2007), Marshall et al. (2015), and
Bonaz and Pellissier (2016).
Modulation of Autonomic Function
Vagus nerve stimulation and aVNS are followed by a broad
physiological multi-level response, as already outlined above.
The stimulation leads to systemic autonomic effects in terms
of the parasympathetic stimulation of the body (He et al.,
2016). The antagonistic action of the activated parasympathetic
system over the sympathetic is one of the expected therapeutic
mechanisms of aVNS, as, for instance, reflected by estimation of
the shift of the ANS activity toward parasympathetic dominance
with reduced sympathetic contribution (Clancy et al., 2014;
Kampusch et al., 2015a).
That is, the sympathovagal balance – or the activity of ANS
(HRV, 1996; Billman et al., 2015) – seems to improve in response
to aVNS, as estimated by its standard measure, HRV (Gbaoui
et al., 2008; Kaniusas et al., 2008; Kampusch et al., 2015b;
Gomolka et al., 2018). For instance, the parasympathetic tone
can be estimated from HRV during respiration cycle (HRV,
1996). While a shift toward parasympathetic predominance
was indicated in aVNS by a decreased ratio of low-frequency
to high-frequency (LF/HF) components of HRV (Deuchars
et al., 2017), muscle sympathetic nerve activity (derived by
microneurography), as a marker for the total sympathetic
outflow, decreased (Clancy et al., 2014). However, authors in De
Couck et al. (2016) and Antonino et al. (2017) report on partly
diverging results on HRV in response to aVNS.
Baseline values seem to have an influence on the autonomic
response due to aVNS or VNS. For instance, a higher resting
ratio LF/HF predicted its greater decrease during aVNS in healthy
humans, implying that humans with higher sympathetic activity
are subjected to a stronger aVNS effect (Clancy et al., 2014).
However, the invasive VNS in epilepsy patients showed an
inverse behavior, in that a higher parasympathetic activity, e.g.,
a higher HF level, led to a better therapeutic outcome of VNS
(Liu et al., 2017).
Modulation of Metabolic Syndrome
Reduced activity of VN, especially, decreased parasympathetic
and increased sympathetic activity, are hypothesized to underlie
metabolic syndrome (De Couck et al., 2011). Therefore VNS and
aVNS can be expected to reduce risks of metabolic syndrome that
includes obesity, elevated glucose levels, diabetes, elevated blood
pressure, and increased inflammation (Pavlov and Tracey, 2012).
In animals, VNS is associated with the weight loss, reduced
fat mass, and decreased appetite (Sobocki et al., 2005; Browning,
2010; Banni et al., 2012). For instance, VNS decreased weight
gain, food consumption, and sweet craving in adult obese
minipigs in the context of morbid obesity (Val-Laillet et al., 2010;
Cork, 2018). aVNS reduced body weight in rats and the amount
of the white adipose tissue in viscera (Li et al., 2015b), indicating
an important role of VN in obesity management. Interestingly,
an imbalance in ANS with predominant parasympathetic activity
is suggested to cause obesity in rats (Barella et al., 2014). aVNS
showed antidiabetic effects in rats through triggered secretion
of melatonin involved in the regulation of glucose metabolism
(Wang S. et al., 2015) and through reduced diabetic cellular injury
(Mei et al., 2013). This is because VN is strongly involved in the
glucose metabolism and insulin secretion (Barella et al., 2014).
In humans, a reduction of body weight and body mass index
was observed in chronically obese females in response to aVNS
in a clinical trial (Schukro et al., 2013). This is in line with a case
series in Szeles et al. (2001) in which the tendency of aVNS to
reduce body weight and body mass index in adipose patients was
observed. aVNS seems to affect appetite and satiety, inhibiting
food intake and thus body weight (Schukro et al., 2013), as well
as seems to affect glucose metabolism, as reviewed in Guiraud
et al. (2016), with a potential impact on the reward system in
the brain. Here the arcuate nucleus of the hypothalamus seems
to play an important role in mediating the satiety in response
to aVNS. In addition, aVNS and the associated raised serotonin
levels have been shown to increase the tone in smooth muscles
of the stomach and to enhance intestinal motility, suppressing
appetite and contributing to the loss of body weight in obese
people, as shown in a clinical trial in Richards and Marley (1998)
and reviewed in Ergene and Tan (2006).
In obese humans, the food signaling from the stomach is
altered as a consequence of the reduced sensitivity of small
intestinal VN afferents, so that aVNS seems to have the potential
to restore this missing or altered signaling, as reviewed in
Guiraud et al. (2016). This is in close analogy with the presented
hypothesis in Figure 2.
Human studies indicate that low VN activity may underlie
elevated glucose levels, whereas the transcutaneous aVNS
significantly reduced the 2-h glucose tolerance (Huang et al.,
2014). aVNS was shown to decrease glycated hemoglobin, blood
urea nitrogen, serum creatinine, total cholesterol, and aspartate
transaminase in patients with type 2 diabetes mellitus (Ju
et al., 2014). Both referenced clinical trials show the potential
of aVNS as a preventive treatment for pre-diabetes and as a
complementary treatment of diabetes patients, respectively.
Modulation of Cardiovascular Effects
Vagus nerve stimulation effects – especially effects of the
parasympathetic modulation (Olshansky et al., 2008) –
on hemodynamic and cardiovascular control have been
demonstrated (Ness et al., 2000; De Ferrari and Schwartz,
2011). However, consistent and significant changes in
hemodynamic measures are usually absent at relatively low
VNS intensities (e.g., below levels used for seizure control in
humans) that are accompanied by pronociception, whereas
hemodynamic measures are invariably altered at higher VNS
intensities, especially at intensities with antinociceptive effects
(Ness et al., 2000).
In animals, invasive VNS attenuated mean arterial blood
pressure and reduced the number of arrhythmia episodes in
hypertensive rats (Annoni et al., 2015), whereas it increased
coronary flow in dogs (Tiedt and Religa, 1979). aVNS elicited
cardiovascular responses in rats, characterized by a lowered blood
pressure (Mahadi et al., 2019) and heart rate (Gao et al., 2007).
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Cardiovascular inhibition in rats due to aVNS was also shown
in Gao et al. (2010), where reduced blood pressure and heart
rate were paralleled by excitation of cardiac-related neurons in
NTS. Similarly, vasodepressor and bradycardic effects of VNS
were attenuated by local anesthetic blockage of NTS (Randich
and Aicher, 1988). In dogs, the protective anti-arrhythmic
role of VNS was shown in terms of preventing ventricular
fibrillation after healed myocardial infarction (Vanoli et al., 1991).
Interestingly, there are indications that a strong invasive VNS
tends to facilitate atrial fibrillation, whereas a moderate VNS
tends to inhibit atrial fibrillation without arrhythmogenic risks
(Chen et al., 2015a).
In humans, an increased cerebral blood flow was found in
certain brain regions associated with afferent pathways of VN
on acute activation of VNS, as shown in a clinical trial in
Conway et al. (2006). aVNS was also reported to increase the
velocity of cerebral blood flow in the supratrochlear artery and
the middle cerebral artery in single patients (Széles and Litscher,
2004). aVNS decreased the carotid-femoral pulse wave velocity,
as shown by a clinical trial in Hackl et al. (2017).
Auricular vagus nerve stimulation reduced the systolic blood
pressure over time in patients with impaired glucose tolerance
(Huang et al., 2014) and in patients with coronary artery
disease (Zamotrinsky et al., 2001), both studies are clinical
trials. The trial in Zamotrinsky et al. (2001) showed markedly
reduced sympathetic inflow to the heart in patients with coronary
artery disease treated with the percutaneous aVNS. In general,
aVNS decreased the heart rate, the systolic blood pressure,
and improved the left ventricular diastolic filling and ejection
fraction. A clinical trial in Badran et al. (2018b) demonstrated
different changes in the heart rate in response to various
aVNS parameters.
As shown in the following clinical trials in humans, aVNS
suppressed atrial fibrillation in patients with paroxysmal atrial
fibrillation (Stavrakis et al., 2015) and improved cardiac function
in patients with coronary artery disease via upregulation of
the protective heat shock proteins and reduction of the heart
rate (Afanasiev et al., 2016). Furthermore, aVNS led to relief
of anginal symptoms in coronary artery disease patients who
underwent coronary artery bypass grafting operations, see a
clinical trial in Zamotrinsky et al. (1997). Here aVNS resulted
in diminution of biochemical myocardial signs of the disease, an
increase in the heart’s tolerance of operative reperfusion damage,
and a reduced need for vasodilators.
Heart failure is another relevant condition for neuromodu-
lation (Stavrakis and Po, 2015), characterized by a chronic
autonomic imbalance with reduced VN activity and accelerated
sympathetic activity (Olshansky et al., 2008; De Ferrari and
Schwartz, 2011; Byku and Mann, 2016). In animals, VNS
was proposed as a potential treatment of heart failure and
angina pectoris (Bilgutay et al., 1968). VNS improved the
long-term survival of rats with chronic heart failure through
the prevention of pumping failure and cardiac remodeling (Li
et al., 2003). VNS improved HRV and baroreflex sensitivity
in a dog model of heart failure, in close association with
a reduction in the expression of inflammatory cytokines
and attenuated development of heart failure (Zhang et al.,
2009). Beneficial effects of VNS may include anti-adrenergic
effects at central and peripheral levels, anti-apoptotic effects,
an increase in nitric oxide (NO), and anti-inflammatory
effects (Olshansky et al., 2008; De Ferrari and Schwartz, 2011). In
humans, aVNS acutely improved the spontaneous cardiac
baroreflex sensitivity, as shown by a clinical trial (Antonino
et al., 2017). A wealth of clinical studies shows that increased
vagal activity reduces the risk of ischemia-related mortality, see
clinical trial in De Ferrari et al. (2010). Thus, heart failure may
favorably be treated by the invasive VNS in humans (De Ferrari
et al., 2010) through blunted sympathetic activity and suppressed
proinflammatory cytokines, as reviewed in Guiraud et al. (2016).
However, more recent clinical trials in heart failure failed to show
efficacy of VNS with respect to reduced rates of death (Gold et al.,
2016). Since stimulation effects of the invasive VNS and aVNS
were shown to be similar in reviews of Beekwilder and Beems
(2010) and Mercante et al. (2018b), it can be hypothesized that
aVNS could be favorably applied in heart failure, as reviewed in
Wang Z. et al. (2015) and He et al. (2016).
Microcirculation is also potentially subjected to aVNS. Release
of vasodilating NO may be involved in mediating cardiovascular
responses to aVNS, as mentioned in Sator-Katzenschlager
and Michalek-Sauberer (2007), leading to enhanced peripheral
perfusion. NO acts also as a ubiquitous sympatholytic and
vagotonic messenger for intracellular signaling in central and
peripheral regions of the autonomous control, e.g., the neuronally
mediated NO increases NTS neuronal activity and inhibits
central sympathetic outflow (Chowdhary and Townend, 1999).
It may be hypothesized that the neuronally mediated NO can
be released through the gracile nucleus-thalamic pathway in
response to the afferent input and/or input from the dorsal
horn neurons (Rong and Ma, 2011), which were reported to
be activated by projections from the great auricular nerve co-
stimulated by aVNS (Mahadi et al., 2019). In addition, since
the anti-inflammatory effects of VNS on the vascular level
prevented an inflammation-related inhibition of NO release in
vascular endothelium (Chapleau et al., 2016), aVNS with its anti-
inflammatory effects may be hypothesized to improve vascular
function through endothelial NO release.
Following the modulation of ANS by aVNS, the capillary-
venous oxygenation in deep tissues under the skin (at about
8 mm) was observed to increase in diabetic patients, indicating
aVNS effects on vasotonus, as indicated by our clinical trial
(Kaniusas et al., 2015). An absolute increase in the mean skin
temperature was observed in response to aVNS in single patients
with peripheral arterial disease and chronic diabetic wounds,
whereas a widening and shrinking of high and low temperature
skin regions, respectively, was observed, as shown by a case series
in Szeles et al. (2013) and our clinical trial (Clodi, 2016).
Therefore, aVNS may potentially improve healing of diabetic
wounds. Here the potential contributors are an increased local
blood perfusion and reduced local inflammation, as indicated by
our clinical trial in Kaniusas et al. (2015) and Thomas (2017), an
increased temperature of the wound region, see our clinical trial
in Clodi (2016) and a case series in Szeles et al. (2013), as well
as a normalized sympathovagal balance toward parasympathetic
predominance due to aVNS, as reviewed in Clayton and Elasy
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(2009) and shown by our clinical trial (Kampusch et al., 2015b).
aVNS in combination with platelet rich fibrin was observed to
contribute to avoidance of amputations due to chronic lower
leg ulcers resistant to conventional treatment in clinical routine,
see a case series in Leitner et al. (2015). Thus, it may be
hypothesized that a multimodal therapeutic concept including
aVNS contributes to a better prognosis of patients with diabetic
foot syndrome and facilitates a conversion of chronic into
active wounds (with their possible closure) avoiding debilitating
amputations. Clearly, further studies are certainly needed to
reveal underlying mechanisms and prove clinical significance of
aVNS in the wound treatment.
Auricular vagus nerve stimulation significantly improved
symptoms in peripheral arterial occlusive disease through
significantly increased pain-free walking distance, as shown in a
case series in Payrits et al. (2011). However, a clinical trial in Hackl
et al. (2017) has shown a significant increase in the initial walking
distance in both verum and control groups, whereas the total
scope of the Walking Impairment Questionnaire significantly
improved only in the verum group.
In patients with the primary Raynaud syndrome, no
significant changes in the skin perfusion and temperature were
observed in response to aVNS, as shown by a case series
in Schlager et al. (2011); however, aVNS still reduced attack
frequency in these patients.
Modulation of Cardioprotective Effects
Ischemic myocardial infarction is resolved by a timely
reperfusion of the occluded coronary artery, which results
in a robust reduction of the acute mortality but also results in an
increased incidence of chronic heart failure. Paradoxically,
reperfusion itself causes injury to the tissue, known as
myocardial reperfusion injury. In particular, the reperfusion
of the jeopardized myocardium is connected with contractile
dysfunction, adverse left ventricular remodeling, cell necrosis,
and inflammatory response (potentially leading to remote
vascular injury). The severity of the myocardial reperfusion
injury is tightly related to parasympathetic hypoactivity and
sympathetic hyperactivity (Florea and Cohn, 2014), which is
qualitatively in line with the discussed autonomic imbalance
in heart failure in humans. Therefore, reestablishment of the
sympathovagal balance via the parasympathetic activation –
using VNS or aVNS – seems to be a potential therapeutic strategy
(Byku and Mann, 2016).
In a rat model, the invasive VNS reduced the infarct size
and ameliorated myocardial dysfunctional vasoconstriction and
vasodilatation after myocardial ischemia and reperfusion (Zhao
et al., 2013). These cardio-protective effects of VNS were
associated with a marked reduction in inflammatory markers, i.e.,
pro-inflammatory cytokines (Calvillo et al., 2011). VNS applied
during acute myocardial ischemia markedly reduced arginase
expression in the myocardium and aorta (as induced by ischemia
and reperfusion), and further elucidated the cardio and vascular
protective effect of VNS (Kiss et al., 2017). In a swine model,
VNS reduced infarct size, ventricular fibrillation incidence,
and improved cardiac function in the course of strengthened
parasympathetic activity (Shinlapawittayatorn et al., 2014).
Cervical VNS was particularly shown to release NO by
neurons (and potentially by myocardial cells) in the heart of
rabbits, in addition to the basal NO produced by endothelial cells
(Brack et al., 2009). NO is suggested to enhance the cardiac vagal
control while buffering sympathetic activity in terms of VNS-
mediated cardioprotection (Chowdhary and Townend, 1999;
Brack et al., 2007). The released NO may account for a number of
VNS effects in the heart, enhancing bradycardia (Chowdhary and
Townend, 1999; Conlon and Kidd, 1999) and ventricular force
control (Brack et al., 2009). There is evidence that NO mediates
the anti-fibrillatory effect of VNS on ventricles (Brack et al., 2007)
and atria (Stavrakis et al., 2013).
Interestingly, an intermittent but not a continuous VNS
attenuated the sympathetic tone and thus reduced the infarct
size after myocardial ischemia and reperfusion; in fact, there is
a strong association between sympathetic stress and infarct size
(Buchholz et al., 2014). In particular, the continuous VNS in
rabbits produced bradycardia and thus long times of the diastolic
ventricular filling, leading to increased atrial and ventricular
volumes, with the consequence that pressures within atria and
ventricles increase. Loading conditions increase, ventricular and
atrial walls are stretched, which, in turn, activate embedded
vagal afferents. This leads to sympathetic compensatory neural
reflexes, potentially responsible for the increase of the infarct
size (Buchholz et al., 2014). In contrast, the intermittent VNS
was not able – or was not intense enough – to increase
these loading conditions but antagonized intermittently the
sympathetic system, reducing the infarct size; compare with the
aforementioned effects of strong VNS versus moderate VNS to
cease atrial fibrillation.
In analogy with VNS, aVNS was shown to reverse cardiac
remodeling, improve cardiac function, and reduce infarct size
in dogs with myocardial infarction (Wang et al., 2014a,b). In
particular, left atrial and left ventricular dilatation were reduced,
left ventricular end-systolic and end-diastolic dimensions were
reduced, left ventricular contractile and diastolic functions
improved, ejection fraction improved, and interstitial fibrosis
and collagen degradation attenuated. Authors in Yu et al. (2012)
showed that aVNS was able to reverse atrial remodeling in dogs,
increase the effective refractory period in atria, and thus to inhibit
inducibility of atrial fibrillation.
Modulation of Psychometric Functions
Auricular vagus nerve stimulation was shown to improve
different psychometric functions – as illustrated by the
following clinical trials – including well-being, alertness,
cognitive performance while decreasing negative mood (Kothe,
2009), in line with improvement of well-being in Kraus et al.
(2007). Subjective well-being in terms of reduced nausea
and tiredness was improved by aVNS during and after
oocyte aspiration (Sator-Katzenschlager et al., 2006). Well-
being, activity, and sleep were improved in patients with
chronic cervical pain (Sator-Katzenschlager et al., 2003) and
with low back pain (Sator-Katzenschlager et al., 2004). Anxiety
was reduced in chronic pelvic pain patients (Napadow et al.,
2012). A case series in Szeles et al. (2001) reported aVNS to
improve the general personal and constitutional condition after
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abdominal and accident surgery. Preliminary data suggest that
aVNS positively affects sleep, as shown by a clinical trial in Becker
(2007) and a case series in Szeles et al. (2010). aVNS may also
attenuate postoperative cognitive dysfunction in elderly patients,
as hypothesized in Xiong et al. (2009).
The results of the following clinical trials show that the
transcutaneous aVNS seems to improve associative memory
performance in older individuals, even after a single treatment
session (Jacobs et al., 2015). aVNS enhanced divergent thinking
due to a speculated increase in GABA levels in the brain (Colzato
et al., 2018) and enhanced response selection during action
cascading processes indicating the important role of the increased
GABA and norepinephrine concentrations (Steenbergen et al.,
2015). Relaxing and sedating effects of aVNS were shown in
Litscher et al. (2007) based on a reduced EEG-bispectral index.
These positive psychometric effects of aVNS may be potentially
ascribed to improved control by ANS and to accelerated
parasympathetic activity.
Modulation of Other Functions
Vagus nerve stimulation effects on respiration and
gastrointestinal control have been demonstrated (Ness et al.,
2000). For instance, aVNS was shown to strengthen respiratory
sinus arrhythmia – i.e., the respiratory-induced and vagus-
mediated change in the cardiac interval divided by the tidal
volume (La Marca et al., 2009) – which is proportionally related
to the parasympathetic activity.
The rationale for gastrointestinal control by VNS or aVNS
is that the vagovagal neurocircuitry modulates the enteric
nervous system and thus influences gastric functions (Bonaz
and Pellissier, 2016). For instance, VNS in rats accelerated
gastric emptying, caused a greater relaxation or dilation of the
pyloric sphincter, and increased antral contraction amplitude,
peristaltic velocity but not its contraction frequency (Lu et al.,
2018). Gastric contraction in rats resulted also in response to
aVNS (Gao et al., 2007). aVNS ameliorated burn-induced gastric
dysmotility and improved its emptying in rats (Li et al., 2015a).
Interestingly, cardiovascular and gastric responses were abolished
by blockade of vagal transmission using the muscarinic receptor
blocker atropine, which highlights the involvement of VN in both
responses and in aVNS (Gao et al., 2007).
Auricular vagus nerve stimulation was highly efficient in
treating a single case of refractory dystonia, whereas preliminary
data suggest both an immediate effect of aVNS on motor
control loops and even sustainable long-term effects on ANS,
see a case study in Kampusch et al. (2015a). aVNS improved
spinal mobility in pain affected patients, see a case series in
Kletzl (2012). aVNS reduced tinnitus severity when paired with
tailored sound therapy (Lehtimaki et al., 2012) and reduced
sympathetic dominance in tinnitus patients (Ylikoski et al.,
2017), both are case series. Here neuroplastic effects of aVNS
resolving pathological plasticity in the cortex are potentially
involved, as reviewed in Clancy et al. (2012). aVNS was shown
to reduce delivery time besides reduced labor pain, as shown
in a case series in Grünberger et al. (2005). aVNS could
also be beneficial to treat chronic hiccups in response to an
altered VN activity, whereas VN is involved in the afferent
and efferent limbs of the hiccup reflex, as reviewed in Clancy
et al. (2012). Likewise, balancing of VN activity via aVNS could
also be beneficial in some conditions like chronic cough in
order to reduce over-activation of vagal respiratory afferents
(Clancy et al., 2012).
LIMITATIONS
A few indirect but rather seldom unwanted effects can also be
triggered by aVNS due to afferent-efferent vagal reflexes, with
NTS as a potential intermediate stage. The Arnolds ear-cough
reflex is the most dominant reflex, in which mechanical irritation
of the auricular skin with embedded aVN may cause cough.
Other reflexes are ear-gag reflex, ear-lacrimation reflex, ear-
syncope reflex, and vaso-vagal reflex. These vegetative reflexes
can occur with the respective incidence up to a few percent
in the general population (Tekdemir et al., 1998; Ellrich, 2011;
Napadow et al., 2012).
In the transcutaneous aVNS, relatively large surface electrodes
yield diffuse stimulation fields. Therefore, not only aVN but also
other non-vagal fibers in the ear can be expected to be stimulated
(Figure 1A). Relatively strong currents and good electrode
contacts are required for the current stimuli to circumvent
the skin barrier of the ear and still stay suprathreshold in
regions innervated by aVN; however, the transcutaneous aVNS
is considered as safe (Badran et al., 2018b). The remaining
side effects are mostly minor – as related to invasive VNS
(Liporace et al., 2001) – and may include headache, pain and skin
irritation at the stimulation site, and dizziness (Mertens et al.,
2018). In contrast to the transcutaneous aVNS, the auricular
needle electrodes in the percutaneous aVNS and the resulting
focused stimulation favor precise and local stimulation of aVN
endings. Here the electrode contact impedance is lower and
more reproducible, favoring a low current stimulation. Minor
side effects are local skin irritation, local bleeding, local pain,
and dizziness. The clinical incidence of skin irritation and
inadvertent bleeding can be reduced down to only 0.05% using
a transillumination technique of the ear (Kaniusas et al., 2011),
which visualizes auricular vessels to avoid random placement of
needles (Roberts et al., 2016).
A special recognition is required on the recent controversy
on whether the stimulation effects of aVNS are due to the
recruitment of aVN and on the true anatomical location of aVN.
The literature on the definite innervation of the auricle is very
sparse and is usually based on often cited findings in Peuker
and Filler (2002), which unfortunately show some inconsistencies
with respect to aVN innervation regions (Burger and Verkuil,
2018). These uncertainties impede a proper interpretation of
stimulation effects while an optimal target for aVNS is still under
debate (Badran et al., 2018a; Burger and Verkuil, 2018).
Auricular vagus nerve stimulation is typically performed at
the tragus or (cavum, cymba) concha (Yakunina et al., 2016).
However, some approaches cover larger areas of the auricle
(Sator-Katzenschlager and Michalek-Sauberer, 2007) with the
potential to stimulate concomitantly a few more auricular nerves
in addition to aVN, especially the great auricular nerve (with
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connections to the spinal cord) or the auriculotemporal nerve
(connecting to the nucleus spinalis of the trigeminal nerve).
Due to a possible co-activation of the great auricular nerve, it
may make sense to study in future the activation of spinal cord
sites, e.g., dorsal horn activity (Deuchars et al., 2017). However,
current imaging studies in humans are usually focused on VN-
activated brain stem nuclei and their projections (Yakunina
et al., 2016). In rats, as reported recently in Mahadi et al.
(2019), tracing of the transcutaneous stimulation at the tragus
labeled the dorsal horn of the cervical spinal cord. Here, a
central sympathoinhibition by up to 36% was observed in
response to the stimulation, as mediated at least in part through
sensory afferent projections to the spinal cord and despite
of only sparse labeling of NTS, the termination site of aVN
(Figure 1A). Authors in Mahadi et al. (2019) also suggest that
the tragus stimulation can indirectly influence brainstem regions
involved in the sympathetic control via the spinal cord and even
suggest an indirect innervation of NTS by recruited aVN via
the spinal cord.
It is questioned if the tragus includes aVN endings
or only non-vagal endings, such as the great auricular
nerve and the auriculotemporal nerve (Badran et al., 2018a;
Burger and Verkuil, 2018). A potential recruitment of these
nerves would suggest that mechanisms may be involved for
tragal stimulation beyond those anticipated for the sole aVN
stimulation. Only the cymba concha was found so far to be
solely innervated by aVN (Peuker and Filler, 2002) with the
associated maximum activation of vagal projections in NTS
during stimulation, as compared to tragus, cavum concha, or
earlobe stimulation (Yakunina et al., 2016). However, the cymba
concha offers some disadvantages in terms of complexity of
electrical stimulation by requiring to insert and/or hold an
electrode against the concha, as opposed to having to clip
onto the tragus.
Lastly, laterality of aVNS is debated. The stimulation of the left
or right aVN cannot be expected to yield different physiological
effects since afferent information from both sides are centrally
merged in the brainstem (Chen et al., 2015b), and the right
and left aVN show comparable counts of Aβ fibers (Safi et al.,
2016). This is in clear contrast to the invasive cervical VNS with
dominant lateral effects, in which, for instance, the right side
stimulation recruits predominantly the sinoatrial node (e.g., with
the associated bradycardia) and the left side the atrioventricular
node. However, simultaneous activation of the left and right aVN
may potentially boost stimulation effects due to increased sensory
input to the brainstem.
FUTURE DIRECTIONS
Even though clinical effects of aVNS and functional projections
of aVN are quite consistent, anatomical projections of auricular
nerves still lack clarity (Burger and Verkuil, 2018). This
complicates identification of biophysical mechanisms, especially
in cardiovascular responses (Mahadi et al., 2019) as well as in
nociception, and thus warrants further anatomical or chemical
tracing studies.
The experimental and clinical efficiency of different
stimulation patterns needs to be investigated, not only on
the local auricular level – as accessible with neuronal models –
but also on the systemic body level. The relevance of such
investigations is indirectly requested by observations that a
strong VNS tends to facilitate atrial fibrillation, whereas a
moderate VNS tends to inhibit it (Chen et al., 2015a). Likewise,
the intermittent VNS attenuated the sympathetic tone but not the
continuous VNS (Buchholz et al., 2014), whereas hemodynamic
changes were observed only at relatively high VNS intensities
(Ness et al., 2000).
Reported data on VNS and aVNS should be interpreted in
light of different stimulation methods used in VNS and aVNS and
even different methods within aVNS itself (Kaniusas et al., 2019).
In fact, aVNS can be operated as the percutaneous stimulation
with a quite focused recruitment of local auricular nerves or as
the transcutaneous stimulation with a rather diffuse stimulation
and thus a potential recruitment of aVN and non-vagal endings.
However, it is important to recognize that whether aVN is
stimulated, either itself or with/without other auricular nerves,
is potentially less important than recognizing that the clinical
effects in humans are real. Here Figure 3 illustrates clinical
applications and the relevance of the associated scientific reports
that substantiates the authenticity of aVNS effects. It should
be noted that the used selection of publications is potentially
biased since the present review is a descriptive but not a
systematic review.
The prediction of responsiveness to aVNS (or VNS) needs
further investigations with respect to baseline conditions of
patients as well as their gender and age. For instance, baseline
conditions in HRV parameters have shown different influence
in VNS and aVNS (Clancy et al., 2014; Liu et al., 2017), which
potentially indicates different mechanisms of action behind VNS
and aVNS. Even in aVNS alone, HRV studies delivered diverging
results (De Couck et al., 2016; Antonino et al., 2017).
Further basic research in animals and humans is clearly
warranted in order to identify and understand reproducible
aVNS biologic effects on the single organ and at the
systemic level. The transition of animal aVNS models to
humans is hardly addressed and should be investigated.
The clinical potential of aVNS in treating different medical
conditions should be clarified based on solid and prospective
clinical studies in humans, whereas aVNS is typically
applied for multimodal disease management. For instance,
aVNS effects are rather consistent in chronic but not
acute pain (Sator-Katzenschlager and Michalek-Sauberer,
2007). Sustainable physiological effects of aVNS in humans
should be quantified.
The paired delivery of VNS and rehabilitative training –
known as Paired Vagus Stimulation – indicates improved task-
specific plasticity in the brain, providing a more effective
rehabilitation. The paired approach was tested in stroke
(Dawson et al., 2015), tinnitus (De Ridder et al., 2013),
post-traumatic stress disorders (Peña et al., 2012), and other
diseases (Hays, 2015). This may indicate potential advantages
of aVNS pairing with rehabilitative stimuli that call for future
research in this area.
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CONCLUSION
Auricular vagus nerve stimulation modulates parasympathetic
activity of the body inhibiting detrimental sympatho-
dominant processes, improves peripheral perfusion due to
decreased sympathetic activity, and reduces over-inflammation.
Arguable, aVNS has likely a great potential to treat numerous
diseases linked with ANS. aVNS may eventually serve as
an alternative to reduce opioid use in chronic disease,
potentially helping to fight the opioid crisis. Most clinical
effects sustain the end of aVNS application, indicating the
presence of long-lasting aVNS effects due to inert processes
such as the release of neurotransmitters and endorphins,
long-term brain plasticity, and self-sustaining changes in the
sympathovagal balance.
Auricular vagus nerve stimulation is not close to prime
time but gains momentum as a new way of treatment by
harnessing the body’s own protective mechanisms beyond the
mediation of symptoms, warranting further scientific and clinical
research on aVNS. aVNS makes possible to modulate the mind’s
great influence over the body via the vagus nerve. An exciting
new therapeutic era may begin allowing clinicians to use both
electroceuticals and pharmaceuticals in a complementary way for
the clear benefit of patients.
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